A Humanized Monoclonal Antibody to Secreted Frizzled Related Protein-2 as a Targeted Therapy for Triple Negative Breast Cancer

2021 ◽  
Vol 233 (5) ◽  
pp. S31
Author(s):  
Julie B. Siegel ◽  
Dean M. Connor ◽  
Patrick Nasarre ◽  
Rupak Mukherjee ◽  
Eleanor Hilliard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Monoclonal Antibody ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Related Protein ◽  
Humanized Monoclonal Antibody

scholarly journals Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2978
Author(s):  
Chia-Jung Li ◽  
Yen-Dun Tony Tzeng ◽  
Yi-Han Chiu ◽  
Hung-Yu Lin ◽  
Ming-Feng Hou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
High Efficiency ◽  
Early Recurrence ◽  
New Developments ◽  
Great Progress ◽  
Low Toxicity ◽  
Made In

Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.

scholarly journals Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer

2020 ◽  
Vol 39 (1) ◽  
Author(s):  
Simona Camorani ◽  
Margherita Passariello ◽  
Lisa Agnello ◽  
Silvia Esposito ◽  
Francesca Collina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Immune Checkpoint ◽  
Triple Negative ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

Acid-labile polysaccharide prodrug via lapatinib-sensitizing effect substantially prevented metastasis and postoperative recurrence of triple-negative breast cancer

Nanoscale ◽  
2020 ◽  
Vol 12 (25) ◽  
pp. 13567-13581 ◽  
Author(s):  
Junhui Sui ◽  
Mingda Zhao ◽  
Yuedi Yang ◽  
Zhihao Guo ◽  
Mengcheng Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapy ◽  
Triple Negative Breast Cancer ◽  
Molecular Targeted Therapy ◽  
Triple Negative ◽  
Postoperative Recurrence ◽  
Sensitizing Effect ◽  
Acid Labile

Co-delivery of lapatinib and Dox by polysaccharide prodrug prevented metastasis and recurrence of triple-negative breast cancer (TNBC) that is usually insensitive to endocrine and molecular targeted therapy.

Sign in / Sign up

Export Citation Format

Share Document